Quinn Opportunity Partners’s Myriad Genetics MYGN Stock Holding History

Quinn Opportunity Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$53.1K	–	373
2025 Q2	$53.1K	Buy	+10,000	New	+$59.1K	﹤0.01%	342
2015 Q4	–	Sell	-29,000	Closed	-$1.17M	–	119
2015 Q3	$1.17M	Buy	29,000 +17,000	+142%	+$603K	0.54%	43
2015 Q2	$408K	Hold	12,000	–	–	0.19%	76
2015 Q1	$424K	Hold	12,000	–	–	0.23%	74
2014 Q4	$408K	Buy	+12,000	New	+$426K	0.19%	64

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quinn Opportunity Partners's MYGN Position: Q3 2025 in Review

Quinn Opportunity Partners sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 10,000 shares — an estimated $53.1K sold.

Quinn Opportunity Partners first reported a position in MYGN in Q4 2014 and held it in 5 quarters. The position peaked at $1.17M in Q3 2015. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Quinn Opportunity Partners reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
Quinn Opportunity Partners sold 10,000 Myriad Genetics shares in Q3 2025, an estimated $53.1K.
Quinn Opportunity Partners first reported a position in Myriad Genetics in Q4 2014 and held it in 5 quarters.
Quinn Opportunity Partners's Myriad Genetics position peaked at $1.17M in Q3 2015.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Quinn Opportunity Partners's 13F filing for Q3 2025, filed 13 Nov 2025.